Aprea Therapeutics, Inc. — Form 8-K Summary
Report date: March 26, 2024. The filing reports the issuance of a press release covering financial results and operating updates for the three and twelve months ended December 31, 2023. Aprea is a Delaware biotechnology company whose common stock trades on Nasdaq under the symbol APRE.
Financial results and operating metrics
The filing states that the company released financial results for the three and twelve months ended December 31, 2023, but the text of the Form 8-K does not provide specific revenue, net income or loss, cash flow, margins, debt, cash, liquidity, or other financial figures. Those details are contained in Exhibit 99.1, which is referenced but not included in the provided filing text.
Material changes versus the prior comparable period
The provided text does not identify specific year-over-year or quarter-over-quarter changes. It only indicates that the company issued an operational update covering the same reporting periods.
Guidance, outlook, risks, and unusual items
- The company updated its corporate presentation on March 26, 2024; the presentation is filed as Exhibit 99.2 and incorporated by reference.
- The filing text does not provide specific guidance, pipeline milestones, clinical results, financing plans, risk updates, contingencies, or unusual items.
- Item 2.02 information, including the press release, is furnished rather than filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference except where expressly stated.
Key facts for investors to verify
- Review Exhibit 99.1 for the actual 2023 financial statements, cash position, operating expenses, net loss, cash burn, and management commentary.
- Review Exhibit 99.2 for updated corporate, clinical-development, regulatory, financing, and outlook information.
- Confirm whether the exhibits contain forward-looking statements, material liquidity constraints, financing requirements, or risks not summarized in the Form 8-K body.
- Note that the filing identifies Aprea as an emerging growth company and states that it has elected the extended transition period for new or revised accounting standards.